Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Capital Expenditures history runs 13 years deep, the most recent figure standing at $23000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 73.26% year-over-year to $23000.0 in Q1 2026; TTM through Mar 2026 was $432000.0, a 27.64% decrease from a year earlier, with the FY2025 full-year figure at $495000.0, down 3.13% from the prior year.
• Capital Expenditures retreated to $23000.0 in Q1 2026 per VRDN's latest filing, from $240000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $566000.0 in Q3 2022 and bottomed at -$186000.0 in Q4 2022.
• The 5-year median for Capital Expenditures is $114500.0 (2023), against an average of $144187.5.
• Across the five-year window, Capital Expenditures sank 359.42% in 2022 and jumped 284.92% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at -$186000.0 in 2022, then jumped by 125.81% to $48000.0 in 2023, then surged by 137.5% to $114000.0 in 2024, then jumped by 110.53% to $240000.0 in 2025, then slumped by 90.42% to $23000.0 in 2026.
• Per Business Quant, the three latest VRDN Capital Expenditures figures stand at $23000.0 (Q1 2026), $240000.0 (Q4 2025), and $127000.0 (Q3 2025).